Areas of Excellence

 
 
 
  • ONCOLOGY
    The Comprehensive Oncology Centre offers comprehensive and multidisciplinary cancer management to patients. The Centre comprises a team of medical specialists and professional nurses, is equipped with high-end medical technologies, e.g. image-guided biopsy, Dual Tracer PET/CT (F-18-FDG and C-11-Acetate), TomoTherapy and M6 CyberKnife and endeavours to provide quality clinical diagnosis and the most suitable treatment in various modalities, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy and autologous peripheral blood stem cell transplantation. Supporting services of professional patient counselling, psychological support, pain management, physical fitness and dietary advices are also available.
  • Radiotherapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormone Therapy
    Hormone therapy, also called endocrine therapy, is a cancer treatment that slows or stops the growth of cancer that is dependent on hormones to grow. Hence, hormone therapy is commonly used to treat breast cancers and prostate cancers. It may be given in different ways, such as the oral route, injection, or surgery to remove the hormone-producing organs (ovaries or testes).

    70-80% of breast cancer patients belong to the hormone-receptor positive category. Hormone-receptor positive patients will derive benefits from hormone therapy in the adjuvant setting after breast surgery (Tamoxifen with or without Gonadotrophin releasing hormone analogue for premenopausal patients, and aromatase inhibitors for postmenopausal patients). The duration of hormone therapy in this situation is usually 5 years or longer.

    Hormone therapy is also an effective treatment in metastatic hormone-sensitive breast cancer, and provides substantial tumor control with relatively less toxic side effects when compared to systemic chemotherapy. At the time of development of endocrine resistance, further hormone therapy, such as Fulvestrant or Exemestane, may be used alone or in combination with other targeted therapies, such as the Cyclin-dependent kinases 4/6 inhibitors or the mTOR inhibitors, to overcome endocrine resistance.

    Almost all prostate cancer cells rely on male sex hormone (androgens) to grow. Androgen deprivation therapy (ADT) can thus effectively suppress prostate cancer by eliminating testosterone production from the testes. In intermediate- to high-risk non-metastatic prostate cancer, ADT can be used before and after radiotherapy to enhance tumor control and reduce tumor recurrence, whereas in metastatic prostate cancer, ADT can be used alone or in combination with chemotherapy to palliate symptom and delay disease progression. ADT can be achieved by surgical removal of testes or regular injection of Luteinizing-releasing hormone analogue.

    At the time of acquired endocrine resistance, also called castration resistance, additional hormone therapy, such as antiandrogens or androgen synthesis inhibitors, may be used in combination with ADT to overcome endocrine resistance. Enzulutamide is a new antiandrogen that binds to the androgen receptors of tumor cells to reduce signal transduction and cell proliferation. Abiraterone Acetate is a new androgen synthesis inhibitor that inhibits androgen production from the adrenal glands, tumor cells, and the testes more comprehensively.